BMY Announces CheckMate -017, -063 Trials Evaluating Opdivo in Previously Treated Squamous NSCLC Show Sustained Survival Benefit

Bristol-Myers Squibb Company BMY today announced longer term survival and safety data from CheckMate -017 and -063, two pivotal trials evaluating Opdivo in previously treated squamous (SQ) non-small cell lung cancer (NSCLC), showing sustained survival benefit across these studies. In both trials, Opdivo showed an estimated 18 month overall survival (OS) rate of 27% (CheckMate -063) to 28% (CheckMate -017); survival benefit was independent of PD-L1 expression. The safety profile of Opdivo is consistent with previously-reported trials, and in CheckMate -017, is also favorable compared to docetaxel. These data will be presented today at the 16th World Conference on Lung Cancer (Abstract #736, CheckMate -017 and #828, CheckMate -063). See full press release